Business Wire

WA-VIRTUOZZO

15.3.2022 12:02:04 CET | Business Wire | Press release

Share
Virtuozzo to Showcase New PaaS for WordPress and Hybrid Server Solutions at CloudFest 2022

Virtuozzo , the alternative cloud platform leader, announced today that it will preview at CloudFest 2022 two never-before-seen solutions designed to help service providers bring to market modern cloud-based solutions that answer long-ignored market needs. The products are the PaaS-focused Virtuozzo Application Platform for WordPress and Virtuozzo Hybrid Server Lite. Framing their value proposition, Virtuozzo executives will deliver two keynote presentations outlining the current industry trends and landscape shaping the need for those services. The sessions will also introduce practical strategies for service providers to integrate and deploy the new solutions in ways that help them increase competitive positioning while growing their business.

Attendees can visit Virtuozzo, a platinum event sponsor, at Stand C01 throughout the show (March 22 – 24) in Europa-Park, Germany. Additionally, a special on-site promotion will give service providers six months free licensing for key solutions showcased during the conference.

Virtuozzo: Bringing Cloud to All

As a company, Virtuozzo has strategically evolved over the last several years to fill a polarizing void in the cloud enablement market. The most common paths to the cloud leverage hyperscaler or enterprise-centric platforms that are generally inflexible, cost-prohibitive, and too complex for non-specialized end users to manage. This puts many businesses, particularly small- to medium-sized ones, at a disadvantage. Which is where Virtuozzo comes in.

“There was an inherent promise in the beginning that cloud would be easy. Accessible to all. In reality, that is not how things panned out,” said Alex Fine, CEO, Virtuozzo. “Virtuozzo is solving that problem through collaborative partnerships with service providers that empower them to become full-service, alternative cloud providers.”

Virtuozzo develops and delivers the most comprehensive cloud platform stack purpose built for service providers. That infrastructure allows services providers to quickly carve out a wide portfolio of cloud services that are easy to use, easy to manage, and easy to scale. This frees them to then focus on areas where they can strongly differentiate, from the delivery of unique products and skills to high-touch customer support.

Virtuozzo Keynote Presentations

The Service Provider Landscape in 2022: Where is the Low-Hanging Fruit?
March 22 at 3:45 PM CET

Carlos Rego, Virtuozzo’s VP of Strategic Development, addresses the roller coaster ride that has been the experience of hosters, MSPs and cloud providers over the past decade. He provides expert perspective on the complex landscape they currently operate in, how the industry is evolving, and how these service providers can strategically grow their businesses without overly taxing their operations.

WordPress Hosting? It’s Time to Grow Up.
March 23 at 4:40 PM CET

In his second presentation, Carlos Rego will introduce viable revenue-generating opportunities surrounding the booming $500B+ WordPress economy. With new PaaS capabilities via Virtuozzo Application Platform for WordPress targeting business-critical WordPress sites, service providers can strengthen their businesses while helping modernize an enormous ecosystem that can be argued is antiquated today.

Schedule a Meeting

To meet with a Virtuozzo team member on site, contact info@Virtuozzo.com .

About Virtuozzo

Virtuozzo (www.virtuozzo.com ) provides the leading alternative cloud platform for service providers, enabling them to sell cloud services that are more accessible, more affordable and easier to use than hyperscaler solutions. The company’s legacy includes developing the first commercially available container technology and being a major contributor to numerous virtualization and open-source projects for more than 20 years. Today, Virtuozzo cloud solutions are used by more than 700 Cloud Service Providers, Managed Service Providers and Hosting Providers in 80 countries. Virtuozzo is based in Schaffhausen, Switzerland, and has more than 320 employees across the U.S., UK, Europe, and Asia-Pacific.

Link:

ClickThru

Social Media:

https://www.facebook.com/VirtuozzoInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye